The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.
|Number of pages||1|
|Publication status||Published - 2014|
|Event||II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment” - Brazil, Belo Horizonte, United Kingdom|
Duration: 10 Nov 2014 → 13 Nov 2014
|Conference||II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”|
|Period||10/11/14 → 13/11/14|
- insulin glargine
- systematic review
- law suits
Godman, B., de Souza, A. L. C., de Assis Acurcio, F., & Guerra Júnior, A. A. (2014). Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.